ForPatients

by Roche

CRC With Atopic Asthma CRC With Chronic Obstructive Pulmonary Disease CRC With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis Chronic Refractory Cough (CRC) With Non-atopic Asthma Unexplained Chronic Cough

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

Trial Status	Trial Runs In	Trial Identifier
Recruiting	4 Countries	NCT05660850 GA43590

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with a history of chronic cough.

Genentech, Inc. Sponsor	Phase 2 Phase	
NCT05660850 GA43590 Trial Identifiers		
Eligibility Criteria:		
Gender All	Age >=18 Years & <= 80 Years	Healthy Volunteers